Abstract: Recent studies demonstrate that parathyroid hormone (PTH) not only maintains mineral homeostasis through targeting the kidneys and bone, but also exerts its effects on other organs. For instance, PTH induces urate accumulation through inhibiting the expression of the ABCG2 in both the intestine and the kidney. In addition, PTH downregulates the expression of cytochrome P450 (CYP) 3A, a major enzyme for drug metabolism in both the intestine and liver, resulting in the increase of substrate drug exposure. These functions of PTH are mediated through the PTH receptor (PTHR) signaling. Since PTHR exists in various organs, PTH may regulate other, still unspecified transporters or enzymes in the organs that express PTHR.
Parathyroid hormone (PTH) plays an important role in the development of chronic kidney diseasemineral bone disease (CKD-MBD) (1, 2) . Recent studies demonstrate that PTH not only maintains mineral homeostasis through targeting the kidneys and bone, but also exerts its effects on other organs (3) . It is well known that PTH regulates the functions of transporters and metabolizing enzymes (4) (5) (6) (7) (8) (9) . For instance, Nashiki et al. and Segawa et al. found that PTH post-transcriptionally downregulates the type II sodium-dependent phosphate (NaPi) cotransports (Npt2a and Npt2c) in apical membrane of renal tubular cells (5, 6) . It has also been reported that PTH inhibits the activities of Nacetyl transferase 2 (NAT2), which is responsible for the acetylation of isoniazid and vitamin D 25-hydroxylase, a key enzyme in the pathogenesis of calcitriol deficiency in CKD (7, 8) .
We recently found that PTH downregulates ABCG2, a major efflux transporter on plasma membrane for various endogenous and exogenous substances, in small intestine and kidneys (9) . We also found that PTH downregulates cytochrome P450 (CYP) 3A, a major metabolic enzyme for various drugs, in small intestine and liver (10) .
Effect of PTH on ABCG2 activity in small intestine and kidney
Increased frequencies of hyperuricemia and gout have been observed among patients with hyperparathyroidism, whereas parathyroidectomy is known to reduce serum urate levels in these patients (9, (11) (12) (13) (14) (15) (16) . In addition, the results of clinical trials have indicated that the use of teriparatide, PTH (1-34), in treating patients with osteoporotic fractures was associated with the development of hyperuricemia (17) (18) (19) . Recently, Hui et al. demonstrated that serum PTH levels were independently associated with serum urate levels and the frequency of hyperuricemia in a nationally representative sample of the US population (20) . Nabipour et al. also reported that serum urate was positively correlated with serum PTH in community-dwelling older men (21) . In addition, an increased fractional excretion of uric acid and resultant hypouricemia was found in patients with pseudohypoparathyroidism (PHP) who showed a resistance to PTH (22) . These clinical findings suggest a close relationship between PTH and urate metabolism. However, whether and how PTH affects serum urate levels remains unknown.
Two-thirds of the urate in the body is normally excreted through the kidney, while one-third is excreted via the gut (23, 24) . Recently, ABCG2 has been identified as a high-capacity urate exporter that mediates the renal and intestinal urate excretion (24, 25) . The contribution of intestinal ABCG2 to urate excretion could be pronounced in patients with end-stage renal disease requiring dialysis therapy. Based on these findings, we hypothesized that elevated PTH influences urate levels via the regulating ABCG2 activity in CKD.
To address this issue, we examined the effect of PTH on the urate excretion system in the setting of secondary hyperparathyroidism (SHPT) (9) . In SHPT model rats, serum urate level was higher than that of sham group, but such an increase was significantly inhibited by the PTH-lowering treatment by calcimimetic cinacalcet without affecting renal function. Indeed, more severe SHPT was associated with elevated serum urate levels and decreased urate excretion in the intestine and kidney. Further, we conducted a clinical study of dialysis patients with SHPT and found that a cinacalcet treatment resulted in a significant decrease in serum urate levels together with a decrease in PTH levels, and similar to the SHPT rats, there was a significant association between higher serum urate and elevated PTH levels. These results support the causal relationship between serum urate and PTH levels under the SHPT condition.
To clarify the role of ABCG2 on this relationship, the ABCG2 expression was also evaluated in the SHPT condition. The ABCG2 expression was significantly suppressed in the small intestine and kidneys of the SHPT model rats, but these alternations were restored by the treatment with cinacalcet. These results indicate that PTH induced ABCG2 downregulation at plasma membrane in the intestine and kidney and thereby caused urate accumulation.
To further explore the mechanism of this finding, we conducted in vitro experiments using Caco-2 cells, a model of intestinal epithelial cells. In Caco-2 cells, the plasma membrane expression of ABCG2 was directly down-regulated by PTH (1-34) without changing its mRNA level, suggesting the existence of a posttranscriptional regulatory system acting through the PTH receptor (PTHR). Using the cell penetrating cAMP analog and various inhibitors for intracellular signaling, we demonstrated that PTH down-regulates ABCG2 expression on the plasma membrane via the cAMP-PI3K-Akt pathway (Fig. 1) .
Effect of PTH on CYP3A activity in small intestine and liver
It has been well recognized that non-renal drug clearance changes in association with declined renal function (10) . The mechanism of this unexpected phenomena has been unclear. Among the drugmetabolizing enzymes, CYP3A is the most abundant and is mainly present in the liver and small intestine and possess a broad substrate specificity. Thus, CYP3A is the most important drugmetabolizing enzyme for the optimization of drug therapy. Under the CKD condition, it has been reported that CYP3A activity is decreased and consequently, inhibits the metabolism of substrate drugs both in the human clinical studies and the animal experiments. For instance, Okabe et al. reported that plasma tacrolimus concentration, a substrate of CYP3A, was increased in CKD condition (26) .
Previously, Pichette's group highlighted the possibility that PTH contributes to the inhibited CYP3A2 (corresponding to human CYP3A4) expression in primary rat hepatocyte under the CKD condition (27) . Recently, our group has extended our understanding of this regulation by showing that PTH causes the inhibited CYP3A2 expression in the liver and small intestine using SHPT model rats, rat primary hepatocyte and Caco2 cell lines (10) . Importantly, such a reduction of CYP3A expression increased the area-under the curve (AUC) of midazolam, a typical substrate of CYP3A, approximately five times in SHPT rats compared to the sham group. Interestingly, these events observed in SHPT rats were significantly restored by the cinacalcet treatment. These findings indicate that PTH directly suppresses the CYP3A activity both in the small intestine and liver under the SHPT condition. In agreement with our findings, Maass et al. reported that, in a patient who developed hyperparathyroidism after renal transplantation, a cinacalcet treatment reduced the plasma tacrolimus concentration, which led to kidney dysfunction (28) .
Using Caco-2 cell line, we also clarified the mechanism by which PTH inhibits the expression of CYP3A. Based on the in vitro study using cell penetrating cAMP analog and various inhibitors, we demonstrated that PTH-induced elevation of intracellular cAMP downregulates CYP3A through multiple signaling pathways, including PI3K/PKC/PKA/ NFk-B pathway (Fig. 1) .
Conclusion
Parathyroid hormone acts as a hormone for the mineral-bone metabolism through acting on classical target organs, kidney and bone, but also exerts nontraditional functions, such as the regulation of the activities of transporters and metabolizing enzymes. We have recently shown that PTH downregulates the plasma membrane expression of ABCG2 in the intestine and kidney and the activity of CYP3A in the intestine and liver through PTHR signaling. Since ABCG2 and CYP3A both play an important role in the disposition of various drugs, PTH could alter the pharmacokinetics of substrate drugs for ABCG2 or CYP3A in patients with CKD-MBD. Moreover, recent studies revealed that PTHR expresses not only on the kidneys and bone, but also on other various tissues. These facts underscore the possibility that PTH may also regulate the functions of other, still-unspecified transporters or metabolizing enzymes in the tissues that express PTHR.
